Special Issue

Zoonotic Risks and Antibiotic Resistance Trends

Message from the Guest Editor

Zoonotic diseases are infectious diseases that are naturally transmitted from vertebrate animals to humans and vice versa. One important zoonotic concern is the global challenge of antimicrobial resistance, which has been aggravated by the overuse and misuse of antimicrobials agents. Antimicrobial resistance is a global problem that must be conducted under the One Health approach at the human–animal–environment interface.

This Special Issue on "Zoonotic risks and Antibiotics Resistance Trends" invites the submission of research on the human-animal-environment interface, including research that investigates the epidemiology of zoonotic transmission, risk factors, and antimicrobial resistance trends. Manuscripts about bacteria, fungi, parasites, and viruses are particularly encouraged. Additionally, the epidemiology of antimicrobial-resistant determinants and virulence of ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens are welcomed.

Guest Editor

Dr. Adriana Belas

- 1. Faculty of Veterinary Medicine, Universidade Lusófona, Lisboa, Portugal
- 2. CIISA- Centro de Investigação Interdisciplinar em Sanidade Animal, Universidade de Lisboa, Lisboa, Portugal

Deadline for manuscript submissions

closed (31 August 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/112120

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

